Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$18.29 +3.8%	$16.05	$9.57 ▼ $29.86	$2.53B	0.93	1.84 million shs	137,472 shs
AUTL Autolus Therapeutics	$2.54 +2.2%	$1.97	$1.11 ▼ $5.00	$675.47M	1.81	1.56 million shs	111,298 shs
GMTX Gemini Therapeutics	$57.74 +1.5%	$50.23	$1.16 ▼ $14.10	$2.50B	-0.12	189,291 shs	235,086 shs
IBRX ImmunityBio	$2.78 +1.3%	$2.74	$1.83 ▼ $7.48	$2.46B	0.08	6.28 million shs	807,383 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	-5.27%	+0.51%	+12.01%	+55.33%	-38.91%
AUTL Autolus Therapeutics	-6.04%	+5.51%	+17.45%	+84.44%	-44.04%
GMTX Gemini Therapeutics	+1.46%	+8.17%	+7.50%	+39.77%	+22.41%
IBRX ImmunityBio	-5.52%	+1.11%	-10.75%	+10.48%	-56.92%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARWR Arrowhead Pharmaceuticals	3.5526 of 5 stars	3.4	2.0	0.0	3.4	2.1	1.7	0.0
AUTL Autolus Therapeutics	2.5139 of 5 stars	3.5	1.0	0.0	0.0	2.2	3.3	0.6
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IBRX ImmunityBio	2.146 of 5 stars	3.6	1.0	0.0	0.0	2.4	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.75	Moderate Buy	$43.71	147.95% Upside
AUTL Autolus Therapeutics	3.00	Buy	$9.32	274.30% Upside
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A
IBRX ImmunityBio	3.20	Buy	$12.25	347.08% Upside

Current Analyst Ratings Breakdown

Latest AUTL, IBRX, GMTX, and ARWR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/12/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/4/2025	IBRX ImmunityBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/3/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
5/28/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
5/20/2025	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/20/2025	IBRX ImmunityBio	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$4.25 ➝ $5.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$21.00 ➝ $17.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
5/12/2025	IBRX ImmunityBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
5/12/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$3.55M	685.83	N/A	N/A	$1.54 per share	11.45
AUTL Autolus Therapeutics	$10.12M	65.48	N/A	N/A	$1.61 per share	1.55
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A
IBRX ImmunityBio	$14.74M	164.07	N/A	N/A	($0.57) per share	-4.81

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.40	N/A	N/A	21.89	N/A	-45.33%	-12.49%	8/6/2025 (Estimated)
AUTL Autolus Therapeutics	-$220.66M	-$0.88	N/A	N/A	N/A	N/A	-52.82%	-29.67%	8/8/2025 (Estimated)
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A
IBRX ImmunityBio	-$413.56M	-$0.58	N/A	N/A	N/A	-1,310.30%	N/A	-121.88%	8/11/2025 (Estimated)

Latest AUTL, IBRX, GMTX, and ARWR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	IBRX ImmunityBio	-$0.10	N/A	N/A	N/A	$21.95 million	N/A
8/8/2025	Q2 2025	AUTL Autolus Therapeutics	-$0.2329	N/A	N/A	N/A	$12.92 million	N/A
5/12/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	$2.75	+$2.81	$2.75	$116.27 million	$542.71 million
5/12/2025	Q1 2025	IBRX ImmunityBio	-$0.12	-$0.15	-$0.03	-$0.15	$17.50 million	$16.52 million
5/8/2025	Q1 2025	AUTL Autolus Therapeutics	-$0.24	-$0.26	-$0.02	-$0.26	$1.59 million	$8.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A
IBRX ImmunityBio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	0.31	5.15	5.15
AUTL Autolus Therapeutics	N/A	9.24	9.02
GMTX Gemini Therapeutics	N/A	71.49	71.49
IBRX ImmunityBio	N/A	2.22	2.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
AUTL Autolus Therapeutics	72.83%
GMTX Gemini Therapeutics	75.42%
IBRX ImmunityBio	8.58%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
AUTL Autolus Therapeutics	25.70%
GMTX Gemini Therapeutics	12.90%
IBRX ImmunityBio	76.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.10 million	132.16 million	Optionable
AUTL Autolus Therapeutics	330	266.14 million	197.74 million	Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable
IBRX ImmunityBio	590	882.62 million	204.86 million	Optionable

AUTL, IBRX, GMTX, and ARWR Headlines

Recent News About These Companies

ImmunityBio: High Stakes On Anktiva's Growth Amidst FDA Friction And Financial Pressures

July 12, 2025 | seekingalpha.com

ImmunityBio's (IBRX) "Buy" Rating Reaffirmed at D. Boral Capital

July 11, 2025 | americanbankingnews.com

ImmunityBio’s Innovative Approach to Ovarian Cancer: A Phase 2 Study Update

July 9, 2025 | tipranks.com

UK MHRA Approves ImmunityBio’s ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

July 8, 2025 | bakersfield.comB

ImmunityBio (NASDAQ:IBRX) Given Buy Rating at D. Boral Capital

July 8, 2025 | marketbeat.com

UK MHRA Approves ImmunityBio's ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

July 7, 2025 | businesswire.com

ImmunityBio (NASDAQ:IBRX) Shares Gap Up - Here's What Happened

July 7, 2025 | marketbeat.com

Bullish Sentiments for ImmunityBio (IBRX) After Trial Success and FDA Authorization

July 7, 2025 | msn.com

ImmunityBio (IBRX) Rated Buy After FDA Approvals and Pancreatic Cancer Trial Success

July 2, 2025 | msn.com

ImmunityBio (IBRX) Attains FDA’s Expanded Access Authorization for its Cancer BioShield Platform Anchored by ANKTIVA

June 24, 2025 | msn.com

ImmunityBio (NASDAQ:IBRX) Shares Down 5.1% - Here's Why

June 23, 2025 | marketbeat.com

ImmunityBio (NASDAQ:IBRX) Stock Price Down 5.9% - Here's Why

June 17, 2025 | marketbeat.com

ImmunityBio: Lymphopenia Opportunity Could Provoke Short Squeeze

June 12, 2025 | seekingalpha.com

ImmunityBio (IBRX) Jumps 18% on Anktiva Access Expansion

June 10, 2025 | msn.com

15 Stocks That Stole The Show Last Week

June 8, 2025 | insidermonkey.com

Why ImmunityBio, Inc. (IBRX) Skyrocketed Today

June 4, 2025 | insidermonkey.com

ImmunityBio receives FDA Expanded Access authorization for Cancer BioShield

June 3, 2025 | finance.yahoo.com

ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer

June 3, 2025 | businesswire.com

ImmunityBio gets FDA expanded access authorization to treat lymphopenia with Anktiva

June 2, 2025 | msn.com

Why ImmunityBio, Inc. (IBRX) Surged On Thursday

May 30, 2025 | msn.com

10 Firms Drenched in Red Today

May 23, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUTL, IBRX, GMTX, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$18.29 +0.66 (+3.75%)

As of 10:25 AM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Autolus Therapeutics NASDAQ:AUTL

$2.54 +0.05 (+2.17%)

As of 10:25 AM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Gemini Therapeutics NASDAQ:GMTX

$57.74 +0.83 (+1.46%)

As of 07/14/2025

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

ImmunityBio NASDAQ:IBRX

$2.78 +0.04 (+1.28%)

As of 10:25 AM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time